Use of granulocyte colony-stimulating factor plus plerixafor for stem cell mobilization is cost-effective in pretreated patients with non-Hodgkin lymphoma.
Dennis L. Lambert, PhD
Advertisement
Articles by Dennis L. Lambert, PhD
Advertisement
Latest Updated Articles
- Economic Evaluation of Plerixafor for Stem Cell Mobilization
January 19th 2012
Advertisement
Advertisement
Trending on AJMC
1
EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology
2
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
3
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
4
Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered
5